Medicine guide

Desloratadine

5 mg · Tablet, Film Coated

Prescription only
Histamine-1 Receptor Antagonist

Active substance: Desloratadine
Used in: Breathing, airways, allergies and cough
Made by: Lupin Pharmaceuticals, Inc.
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2026-06-30

What it is

Histamine-1 Receptor Antagonist

Used for

Relief of nasal and non-nasal symptoms in patients 12 years of age and older.

The label’s usual adult dose

Adults and Adolescents 12 Years of Age and Over:: desloratadine Tablets - one 5 mg tablet once daily Desloratadine tablets may be taken without regard to meals.

Full directions ↓

Do not take it if

Hypersensitivity ( 4 , 6.2 ) Desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see WARNINGS AND PRECAUTIONS ( 5.1 ) and ADVERSE REACTIONS ( 6.2 )].

All warnings ↓

Good to know

Prescription only
FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02

12other products contain Desloratadine — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

Desloratadine tablets are histamine-1 (H1) receptor antagonist indicated for:

Seasonal Allergic Rhinitis:
relief of nasal and non-nasal symptoms in patients 12 years of age and older.
( 1.1 ) Perennial Allergic Rhinitis:
relief of nasal and non-nasal symptoms in patients 12 years of age and older.
( 1.2 )
1.1 Seasonal Allergic Rhinitis Desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older.
1.2 Perennial Allergic Rhinitis Desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older.

From the official label · 2026-06-30 · DailyMed

How it works

From this product’s own US prescribing label.

Desloratadine is a long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity.
Receptor binding data indicates that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor.

With food

Neither food nor grapefruit juice had an effect on the bioavailability (C max and AUC) of desloratadine.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-30

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

Dosage (by age):
Adults and Adolescents 12 Years of Age and Over:
Desloratadine Tablets - one 5 mg tablet once daily Desloratadine tablets may be taken without regard to meals.
2.1
Adults and Adolescents 12 Years of Age and Over The recommended dose of desloratadine tablets is one 5 mg tablet once daily.
2.5
Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.
Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [see CLINICAL PHARMACOLOGY ( 12.3 )] .

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported.
In such cases, stop desloratadine tablets at once and consider alternative treatments.
( 5.1 )
5.1 Hypersensitivity Reactions Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported after administration of desloratadine.
If such a reaction occurs, therapy with desloratadine should be stopped and alternative treatment should be considered. [See ADVERSE REACTIONS ( 6.2 ).]

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Risk Summary The limited available data with desloratadine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage.
There are no adequate and well-controlled studies in pregnant women.
Desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (AUC)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (RHD) of 5 mg/day.
Desloratadine given during organogenesis to pregnant rabbits was not teratogenic at the AUC-based exposures of desloratadine approximately 230 times that at the RHD.
Desloratadine given to pregnant rats during organogenesis through lactation resulted in reduced body weight and slow righting reflex of F1 pups at the summed AUC-based exposures of desloratadine and its metabolite approximately 70 times or greater than that at the RHD [see Data] .
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data Animal Data:
Desloratadine was given orally during organogenesis to pregnant rats at doses of 6, 24 and 48 mg/kg/day (approximately 50, 200 and 320 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
No fetal malformations were present.
Reduced fetal weights and skeletal variations noted at doses of 24 and 48 mg/kg/day were likely secondary to the maternal toxicities of reduced body weight gain and food consumption observed at the same doses.
Desloratadine was also given orally during organogenesis to pregnant rabbits at doses of 15, 30 and 60 mg/kg/day (approximately 30, 70 and 230 times the AUC- based exposure of desloratadine at the RHD).
No adverse effects to the fetus were noted.
Reduced maternal body weight gain was noted in rabbits at 60 mg/kg/day.
In a peri- and post-natal development study, desloratadine was given to rats orally during the peri- natal (Gestation Day 6) through lactation periods (Postpartum Day 21) at doses of 3, 9 and 18 mg/kg/day.
Reduced body weight and slow righting reflex were reported in F1 pups at doses of 9 mg/kg/day or greater (approximately 70 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
Desloratadine had no effect on F1 pup development at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
Maternal toxicities including reduced body weight gain and food consumption were noted at 18 mg/kg/day for F0 dams.
F1 offspring were subsequently mated and there was no developmental toxicity for F2 pups observed.
8.3 Females and Males of Reproductive Potential Infertility There are no data available on human infertility associated with desloratadine.
There were no clinically relevant effects of desloratadine on female fertility in rats.
A male specific decrease in fertility occurred at an oral desloratadine dose of 12 mg/kg or greater in rats (approximately 65 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
Male fertility was unaffected at a desloratadine dose of 3 mg/kg (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). [See NONCLINICAL TOXICOLOGY ( 13.1 ).]
IN SPECIFIC POPULATIONS Renal impairment:
dosage adjustment is recommended ( 2.5 , 8.6 , 12.3 ) Hepatic impairment:
dosage adjustment is recommended ( 2.5 , 8.7 , 12.3 )
8.1 Pregnancy Risk Summary The limited available data with desloratadine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage.
There are no adequate and well-controlled studies in pregnant women.
Desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (AUC)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (RHD) of 5 mg/day.
Desloratadine given during organogenesis to pregnant rabbits was not teratogenic at the AUC-based exposures of desloratadine approximately 230 times that at the RHD.
Desloratadine given to pregnant rats during organogenesis through lactation resulted in reduced body weight and slow righting reflex of F1 pups at the summed AUC-based exposures of desloratadine and its metabolite approximately 70 times or greater than that at the RHD [see Data] .
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data Animal Data:
Desloratadine was given orally during organogenesis to pregnant rats at doses of 6, 24 and 48 mg/kg/day (approximately 50, 200 and 320 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
No fetal malformations were present.
Reduced fetal weights and skeletal variations noted at doses of 24 and 48 mg/kg/day were likely secondary to the maternal toxicities of reduced body weight gain and food consumption observed at the same doses.
Desloratadine was also given orally during organogenesis to pregnant rabbits at doses of 15, 30 and 60 mg/kg/day (approximately 30, 70 and 230 times the AUC- based exposure of desloratadine at the RHD).
No adverse effects to the fetus were noted.
Reduced maternal body weight gain was noted in rabbits at 60 mg/kg/day.
In a peri- and post-natal development study, desloratadine was given to rats orally during the peri- natal (Gestation Day 6) through lactation periods (Postpartum Day 21) at doses of 3, 9 and 18 mg/kg/day.
Reduced body weight and slow righting reflex were reported in F1 pups at doses of 9 mg/kg/day or greater (approximately 70 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
Desloratadine had no effect on F1 pup development at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
Maternal toxicities including reduced body weight gain and food consumption were noted at 18 mg/kg/day for F0 dams.
F1 offspring were subsequently mated and there was no developmental toxicity for F2 pups observed.
8.2 Lactation Risk Summary Desloratadine passes into breast milk.
There are not sufficient data on the effects of desloratadine on the breastfed infant or the effects of desloratadine on milk production.
The decision should be made whether to discontinue nursing or to discontinue desloratadine, taking into account the developmental and health benefits of breastfeeding, the nursing mother's clinical need, and any potential adverse effects on the breastfed infant from desloratadine or from the underlying maternal condition.
8.3 Females and Males of Reproductive Potential Infertility There are no data available on human infertility associated with desloratadine.
There were no clinically relevant effects of desloratadine on female fertility in rats.
A male specific decrease in fertility occurred at an oral desloratadine dose of 12 mg/kg or greater in rats (approximately 65 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
Male fertility was unaffected at a desloratadine dose of 3 mg/kg (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). [See NONCLINICAL TOXICOLOGY ( 13.1 ).]
8.4 Pediatric Use The recommended dose of desloratadine oral solution in the pediatric population is based on cross-study comparison of the plasma concentration of desloratadine in
adults and pediatric subjects.
The safety of desloratadine oral solution has been established in 246 pediatric subjects aged 6 months to 11 years in three placebo-controlled clinical studies.
Since the course of seasonal and perennial allergic rhinitis and the effects of desloratadine are sufficiently similar in the pediatric and adult populations, it allows extrapolation from the adult efficacy data to pediatric patients.
The effectiveness of desloratadine oral solution in these age groups is supported by evidence from adequate and well-controlled studies of desloratadine tablets in
adults.
The safety and effectiveness of desloratadine tablets or desloratadine oral solution have not been demonstrated in pediatric patients less than 6 months of age. [See CLINICAL PHARMACOLOGY ( 12.3 )].
8.5 Geriatric Use Clinical studies of desloratadine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. [See CLINICAL PHARMACOLOGY ( 12.3 )].
8.6 Renal Impairment Dosage adjustment for patients with renal impairment is recommended [see DOSAGE AND ADMINISTRATION ( 2.5 ) and CLINICAL PHARMACOLOGY ( 12.3 )].
8.7 Hepatic Impairment Dosage adjustment for patients with hepatic impairment is recommended [see DOSAGE AND ADMINISTRATION ( 2.5 ) and CLINICAL PHARMACOLOGY ( 12.3 )].

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

7.1 Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See CLINICAL PHARMACOLOGY ( 12.3 )].
7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See CLINICAL PHARMACOLOGY ( 12.3 )].
7.3 Cimetidine In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See CLINICAL PHARMACOLOGY ( 12.3 )].

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

In the event of overdose, consider standard measures to remove any unabsorbed drug.
Symptomatic and supportive treatment is recommended.
Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis.
Information regarding acute overdosage is limited to experience from post-marketing adverse event reports and from clinical trials conducted during the development of the desloratadine product.
In a dose-ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported.
In another study, no clinically relevant adverse events were reported in normal male and female volunteers who were given single daily doses of desloratadine 45 mg for 10 days [See CLINICAL PHARMACOLOGY ( 12.2 )].

Quoted from the official label, section “Overdosage”.

Misuse and dependence

There is no information to indicate that abuse or dependency occurs with desloratadine tablets.

Quoted from the official label, section “Drug Abuse and Dependence”.

Use in children

The recommended dose of desloratadine oral solution in the pediatric population is based on cross-study comparison of the plasma concentration of desloratadine in
adults and pediatric subjects.
The safety of desloratadine oral solution has been established in 246 pediatric subjects aged 6 months to 11 years in three placebo-controlled clinical studies.
Since the course of seasonal and perennial allergic rhinitis and the effects of desloratadine are sufficiently similar in the pediatric and adult populations, it allows extrapolation from the adult efficacy data to pediatric patients.
The effectiveness of desloratadine oral solution in these age groups is supported by evidence from adequate and well-controlled studies of desloratadine tablets in
adults.
The safety and effectiveness of desloratadine tablets or desloratadine oral solution have not been demonstrated in pediatric patients less than 6 months of age. [See CLINICAL PHARMACOLOGY ( 12.3 )].

Quoted from the official label, section “Pediatric Use”.

Use in older people

Clinical studies of desloratadine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. [See CLINICAL PHARMACOLOGY ( 12.3 )].

Quoted from the official label, section “Geriatric Use”.

Side effects

The most common adverse reactions (reported in ≥2% of adult and adolescent patients with allergic rhinitis and greater than placebo) were pharyngitis, dry mouth, myalgia, fatigue, somnolence, dysmenorrhea.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The following adverse reactions are discussed in greater detail in other sections of the label:
Hypersensitivity reactions. [See WARNINGS AND PRECAUTIONS ( 5.1 ).]
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adults and Adolescents Allergic Rhinitis:
In multiple-dose placebo-controlled trials, 2834 patients ages 12 years or older received desloratadine tablets at doses of 2.5 mg to 20 mg daily, of whom 1655 patients received the recommended daily dose of 5 mg.
In patients receiving 5 mg daily, the rate of adverse events was similar between desloratadine and placebo-treated patients.
The percent of patients who withdrew prematurely due to adverse events was 2.4% in the desloratadine group and 2.6% in the placebo group.
There were no serious adverse events in these trials in patients receiving desloratadine.
All adverse events that were reported by greater than or equal to 2% of patients who received the recommended daily dose of desloratadine tablets (5 mg once daily), and that were more common with desloratadine tablets than placebo, are listed in Table 1.
Table 1 Incidence of Adverse Events Reported by ≥2% of Adult and Adolescent Allergic Rhinitis Patients Receiving Desloratadine Tablets Adverse Event Desloratadine Tablets , 5 mg ( n = 1655 ) Placebo ( n = 1652 ) Infections and Infestations Pharyngitis 4.1% 2.0% Nervous System Disorders Somnolence 2.1% 1.8% Gastrointestinal Disorders Dry Mouth 3.0% 1.9% Musculoskeletal and Connective Tissue Disorders Myalgia 2.1% 1.8% Reproductive System and Breast Disorders Dysmenorrhea 2.1% 1.6% General Disorders and Administration Site Conditions Fatigue 2.1% 1.2% The frequency and magnitude of laboratory and electrocardiographic abnormalities were similar in desloratadine and placebo-treated patients.
There were no differences in adverse events for subgroups of patients as defined by gender, age, or race.
Pediatrics Two hundred and forty-six pediatric subjects 6 months to 11 years of age received desloratadine oral solution for 15 days in three placebo-controlled clinical trials.
Pediatric subjects aged 6 to 11 years received 2.5 mg once a day, subjects aged 1 to 5 years received 1.25 mg once a day, and subjects 6 to 11 months of age received 1.0 mg once a day.
In subjects 6 to 11 years of age, no individual adverse event was reported by 2 percent or more of the subjects.
In subjects 2 to 5 years of age, adverse events reported for desloratadine and placebo in at least 2 percent of subjects receiving desloratadine oral solution and at a frequency greater than placebo were fever (5.5%, 5.4%), urinary tract infection (3.6%, 0%) and varicella (3.6%, 0%).
In subjects 12 months to 23 months of age, adverse events reported for the desloratadine product and placebo in at least 2 percent of subjects receiving desloratadine oral solution and at a frequency greater than placebo were fever (16.9%, 12.9%), diarrhea (15.4%, 11.3%), upper respiratory tract infections (10.8%, 9.7%), coughing (10.8%, 6.5%), appetite increased (3.1%, 1.6%), emotional lability (3.1%, 0%), epistaxis (3.1%, 0%), parasitic infection (3.1%, 0%), pharyngitis (3.1%, 0%), rash maculopapular (3.1%, 0%).
In subjects 6 months to 11 months of age, adverse events reported for desloratadine and placebo in at least 2 percent of subjects receiving desloratadine oral solution and at a frequency greater than placebo were upper respiratory tract infections (21.2%, 12.9%), diarrhea (19.7%, 8.1%), fever (12.1%, 1.6%), irritability (12.1%, 11.3%), coughing (10.6%, 9.7%), somnolence (9.1%, 8.1%), bronchitis (6.1%, 0%), otitis media (6.1%, 1.6%), vomiting (6.1%, 3.2%), anorexia (4.5%, 1.6%), pharyngitis (4.5%, 1.6%), insomnia (4.5%, 0%), rhinorrhea (4.5%, 3.2%), erythema (3.0%, 1.6%), and nausea (3.0%, 0%).
There were no clinically meaningful changes in any electrocardiographic parameter, including the QTc interval.
Only one of the 246 pediatric subjects receiving desloratadine oral solution in the clinical trials discontinued treatment because of an adverse event.
6.2 Post-Marketing Experience Because adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following spontaneous adverse events have been reported during the marketing of desloratadine:
Cardiac disorders:
tachycardia, palpitations Respiratory, thoracic and mediastinal disorders:
dyspnea Skin and subcutaneous tissue disorders:
rash, pruritus Nervous system disorders:
psychomotor hyperactivity, movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures (reported in patients with and without a known seizure disorder) Immune system disorders:
hypersensitivity reactions (such as urticaria, edema and anaphylaxis) Investigations:
elevated liver enzymes including bilirubin Hepatobiliary disorders:
hepatitis Metabolism and nutrition disorders:
increased appetite

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

Advise the patient to read the FDA-approved patient labeling (Patient Information).
17.1 Information for Patients Patients should be instructed to use desloratadine tablets as directed.
As there are no food effects on bioavailability, patients can be instructed that desloratadine tablets may be taken without regard to meals.
Patients should be advised not to increase the dose or dosing frequency as studies have not demonstrated increased effectiveness at higher doses and somnolence may occur.
The brands listed are trademarks of their respective owners and are not trademarks of Lupin Pharmaceuticals, Inc.
The makers of these brands are not affiliated with and do not endorse Lupin Pharmaceuticals, Inc. or its products.
LUPIN and the are registered trademarks of Lupin Pharmaceuticals, Inc.
Manufactured for: Lupin Pharmaceuticals, Inc.
Naples, FL 34108 United States Manufactured by:
Lupin Limited Goa 403 722 INDIA Revised:
August 2025 Image

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

FORMS AND STRENGTHS Desloratadine tablets USP - 5 mg ( 3 ) Desloratadine tablets USP, 5 mg are light blue, circular, biconvex, film-coated tablets, debossed "LU" on one side and "S71" on other side.

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

Desloratadine tablets USP, 5 mg are light blue, circular, biconvex, film-coated tablets, debossed "LU" on one side and "S71" on other side.
They are supplied as follows:
NDC 68180-153-01 Bottles of 100 NDC 68180-153-02 Bottles of 500 Storage:
Store at 25°C (77°F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature].
Heat Sensitive.
Avoid exposure at or above 30°C (86°F).
Dispense in tight, light-resistant container as defined in the USP using a child-resistant closure.

Quoted from the official label, section “How Supplied”.

What is in it

Desloratadine tablets USP, 5 mg are light blue, circular, biconvex, film-coated tablets debossed "LU" on one side and "S71" on other side, containing 5 mg desloratadine, an antihistamine, to be administered orally.
Desloratadine tablets USP also contain the following excipients:
anhydrous lactose, colloidal silicon dioxide, FD&C Blue#2/Indigo Carmine Aluminium Lake, hydrogenated vegetable oil, hypromellose, microcrystalline cellulose, polyethylene glycol, pregelatinised starch and titanium dioxide.
Desloratadine is a white to off-white crystalline powder that is freely soluble in dichloromethane and in methanol.
It has an empirical formula: C 19 H 19 ClN 2 and a molecular weight of 310.8.
The chemical name is 8-chloro-6,11-dihydro-11-(4-piperdinylidene)-5 H -benzo[5,6]cyclohepta[1,2- b ]pyridine and has the following structure:
1

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (11)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 11 of 11

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

European UnionNo exact match for this strength and form

Every strength and form (9)

France16 matching products

Every strength and form (24)

Canada5 matching products

Every strength and form (7)

Netherlands18 matching products

Every strength and form (29)

Details

Made by	Lupin Pharmaceuticals, Inc.
Active substance	Desloratadine
Used in	Breathing, airways, allergies and cough
Strength	5 mg
Form	Tablet, Film Coated
Route	Oral
Packs	100 TABLET, FILM COATED in 1 BOTTLE · 500 TABLET, FILM COATED in 1 BOTTLE
NDC	68180-153

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

11 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Tablet, Film Coated5 products
- 5 mg5
  5 mg · 5 companies
  - A-S Medication Solutions
  - Bionpharma Inc.
  - Bryant Ranch Prepack
  - Lupin Pharmaceuticals, Inc. · this page
  - Natco Pharma USA LLC
Tablet4 products
- 5 mg4
  5 mg · 4 companies
Tablet, Orally Disintegrating2 products
- 2.5 mg
- 5 mg

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Clarinex5 mgPrescription onlyTablet, Film Coated Organon LLC · Desloratadine Desloratadine5 mgPrescription onlyTablet A-S Medication Solutions · Desloratadine Desloratadine5 mgPrescription onlyTablet, Film Coated A-S Medication Solutions · Desloratadine Desloratadine5 mgPrescription onlyTablet, Orally Disintegrating Dr. Reddy's Laboratories Limited · Desloratadine Desloratadine2.5 mgPrescription onlyTablet, Orally Disintegrating Dr. Reddy's Laboratories Limited · Desloratadine Desloratadine5 mgPrescription onlyTablet, Film Coated Natco Pharma USA LLC · Desloratadine

See every product with Desloratadine